Prognostic Factors Associated with 2-year Mortality in Patients with Intermittent Claudication Treated with Endovascular Therapy for Femoropopliteal Lesions: Results from the Multicenter PROCYON Study.

IF 3 2区 医学 Q2 PERIPHERAL VASCULAR DISEASE
Tatsuro Takei, Takahiro Tokuda, Naoki Yoshioka, Kenji Ogata, Akiko Tanaka, Shunsuke Kojima, Kohei Yamaguchi, Takashi Yanagiuchi, Tatsuya Nakama
{"title":"Prognostic Factors Associated with 2-year Mortality in Patients with Intermittent Claudication Treated with Endovascular Therapy for Femoropopliteal Lesions: Results from the Multicenter PROCYON Study.","authors":"Tatsuro Takei, Takahiro Tokuda, Naoki Yoshioka, Kenji Ogata, Akiko Tanaka, Shunsuke Kojima, Kohei Yamaguchi, Takashi Yanagiuchi, Tatsuya Nakama","doi":"10.5551/jat.65379","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>Few studies have evaluated the midterm prognosis of patients with intermittent claudication who underwent endovascular therapy (EVT) for femoropopliteal lesions. Therefore, we aimed to assess 2-year mortality and prognostic factors in these patients.</p><p><strong>Methods: </strong>We retrospectively analyzed 947 patients who underwent EVT for intermittent claudication between January 2018 and December 2021 at eight Japanese cardiovascular centers. Kaplan-Meier survival analysis was performed for mortality, and prognostic factors were analyzed using the Cox proportional hazards regression model. Patient backgrounds and medications were included in the investigation of prognostic factors.</p><p><strong>Results: </strong>Notably, 79 deaths occurred during the mean follow-up period of 20.9±6.2 months. The 2-year mortality rate was 9.1%. In multivariate analysis, body mass index (BMI) <18.5 kg/m<sup>2</sup> (p<0.001), coronary artery disease (CAD) (p<0.001), dialysis (p<0.001), and ankle-brachial pressure index (ABI) <0.6 (p=0.012) were risk factors. Statins and cilostazol were protective factors (p=0.014 and p=0.036, respectively). When the study population was stratified based on the number of these risk factors, the mortality rate was highest (32.5% at 2 years) in patients with at least three risk factors. However, when stratified according to protective factors, the mortality rate was lowest in patients with two protective factors (2.1% at 2 years).</p><p><strong>Conclusions: </strong>Dialysis, low BMI, CAD, and low ABI were risk factors for a worse 2-year prognosis in patients with intermittent claudication who underwent EVT for femoropopliteal lesions. Statins and cilostazol may improve the 2-year prognosis of patients with lower extremity artery disease.</p>","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of atherosclerosis and thrombosis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5551/jat.65379","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: Few studies have evaluated the midterm prognosis of patients with intermittent claudication who underwent endovascular therapy (EVT) for femoropopliteal lesions. Therefore, we aimed to assess 2-year mortality and prognostic factors in these patients.

Methods: We retrospectively analyzed 947 patients who underwent EVT for intermittent claudication between January 2018 and December 2021 at eight Japanese cardiovascular centers. Kaplan-Meier survival analysis was performed for mortality, and prognostic factors were analyzed using the Cox proportional hazards regression model. Patient backgrounds and medications were included in the investigation of prognostic factors.

Results: Notably, 79 deaths occurred during the mean follow-up period of 20.9±6.2 months. The 2-year mortality rate was 9.1%. In multivariate analysis, body mass index (BMI) <18.5 kg/m2 (p<0.001), coronary artery disease (CAD) (p<0.001), dialysis (p<0.001), and ankle-brachial pressure index (ABI) <0.6 (p=0.012) were risk factors. Statins and cilostazol were protective factors (p=0.014 and p=0.036, respectively). When the study population was stratified based on the number of these risk factors, the mortality rate was highest (32.5% at 2 years) in patients with at least three risk factors. However, when stratified according to protective factors, the mortality rate was lowest in patients with two protective factors (2.1% at 2 years).

Conclusions: Dialysis, low BMI, CAD, and low ABI were risk factors for a worse 2-year prognosis in patients with intermittent claudication who underwent EVT for femoropopliteal lesions. Statins and cilostazol may improve the 2-year prognosis of patients with lower extremity artery disease.

经股腘动脉内治疗的间歇性跛行患者2年死亡率相关的预后因素:来自多中心PROCYON研究的结果
目的:很少有研究评估间歇性跛行股骨头病变患者接受血管内治疗(EVT)的中期预后。因此,我们的目的是评估这些患者的2年死亡率和预后因素。方法:我们回顾性分析了2018年1月至2021年12月期间在日本8个心血管中心接受EVT治疗间歇性跛行的947例患者。死亡率采用Kaplan-Meier生存分析,预后因素采用Cox比例风险回归模型进行分析。预后因素的调查包括患者背景和药物。结果:平均随访20.9±6.2个月,死亡79例。2年死亡率为9.1%。在多因素分析中,体重指数(BMI) <18.5 kg/m2 (p<0.001)、冠状动脉疾病(CAD) (p<0.001)、透析(p<0.001)、踝肱压指数(ABI) <0.6 (p=0.012)是危险因素。他汀类药物和西洛他唑是保护因素(p=0.014和p=0.036)。当根据这些危险因素的数量对研究人群进行分层时,至少有三个危险因素的患者的死亡率最高(2年死亡率为32.5%)。然而,当根据保护因素分层时,具有两种保护因素的患者死亡率最低(2年时2.1%)。结论:透析、低BMI、CAD和低ABI是间歇性跛行行EVT治疗股腘动脉病变患者2年预后较差的危险因素。他汀类药物和西洛他唑可改善下肢动脉疾病患者的2年预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.60
自引率
15.90%
发文量
271
审稿时长
1 months
期刊介绍: JAT publishes articles focused on all aspects of research on atherosclerosis, vascular biology, thrombosis, lipid and metabolism.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信